Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia
An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. T...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-12-01
|
| Series: | Contemporary Clinical Trials Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865415300636 |
| _version_ | 1819105670883966976 |
|---|---|
| author | Kenneth F. Bradstock Alec Morley Karen Byth Jeff Szer Ian Prosser Paul Cannell Ian Irving John F. Seymour |
| author_facet | Kenneth F. Bradstock Alec Morley Karen Byth Jeff Szer Ian Prosser Paul Cannell Ian Irving John F. Seymour |
| author_sort | Kenneth F. Bradstock |
| collection | DOAJ |
| description | An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The primary endpoints were induction death rate and incidence of serious non-hematological toxicity. Grades 3–4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia. Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were comparable with those previously observed using a modified pediatric protocol. Overall survival at 5 years was 36.8% while leukemia-free survival was 44.1%. An intensive AML protocol used in adults with ALL resulted in substantial toxicity and provided similar levels of cytoreduction to conventional ALL protocols, without improving long-term outcomes. |
| first_indexed | 2024-12-22T02:25:57Z |
| format | Article |
| id | doaj.art-109c03693b674aa18a3988208ecf64af |
| institution | Directory Open Access Journal |
| issn | 2451-8654 |
| language | English |
| last_indexed | 2024-12-22T02:25:57Z |
| publishDate | 2016-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Contemporary Clinical Trials Communications |
| spelling | doaj.art-109c03693b674aa18a3988208ecf64af2022-12-21T18:42:00ZengElsevierContemporary Clinical Trials Communications2451-86542016-12-014C91310.1016/j.conctc.2016.06.004Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemiaKenneth F. Bradstock0Alec Morley1Karen Byth2Jeff Szer3Ian Prosser4Paul Cannell5Ian Irving6John F. Seymour7Department of Haematology, Westmead Hospital, Sydney, New South Wales, AustraliaFlinders University and Medical Centre, Adelaide, South Australia, AustraliaResearch and Education Network, Westmead Hospital, Sydney, New South Wales, AustraliaRoyal Melbourne Hospital and University of Melbourne, Victoria, AustraliaCanberra Hospital, Australian Capital Territory, AustraliaRoyal Perth Hospital, Perth, Western Australia, AustraliaDepartment of Haematology, Townsville Hospital, Queensland, AustraliaDepartment of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, AustraliaAn intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The primary endpoints were induction death rate and incidence of serious non-hematological toxicity. Grades 3–4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia. Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were comparable with those previously observed using a modified pediatric protocol. Overall survival at 5 years was 36.8% while leukemia-free survival was 44.1%. An intensive AML protocol used in adults with ALL resulted in substantial toxicity and provided similar levels of cytoreduction to conventional ALL protocols, without improving long-term outcomes.http://www.sciencedirect.com/science/article/pii/S2451865415300636Acute lymphoblastic leukemiaAdultsHigh dose cytarabineMinimal residual disease |
| spellingShingle | Kenneth F. Bradstock Alec Morley Karen Byth Jeff Szer Ian Prosser Paul Cannell Ian Irving John F. Seymour Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia Contemporary Clinical Trials Communications Acute lymphoblastic leukemia Adults High dose cytarabine Minimal residual disease |
| title | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia |
| title_full | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia |
| title_fullStr | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia |
| title_full_unstemmed | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia |
| title_short | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia |
| title_sort | effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor b acute lymphoblastic leukemia |
| topic | Acute lymphoblastic leukemia Adults High dose cytarabine Minimal residual disease |
| url | http://www.sciencedirect.com/science/article/pii/S2451865415300636 |
| work_keys_str_mv | AT kennethfbradstock effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT alecmorley effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT karenbyth effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT jeffszer effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT ianprosser effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT paulcannell effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT ianirving effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia AT johnfseymour effectsofintensiveinductionandconsolidationchemotherapywithidarubicinandhighdosecytarabineonminimalresidualdiseaselevelsinnewlydiagnosedadultprecursorbacutelymphoblasticleukemia |